Department of Internal Medicine, Cardiovascular and Immunologic Sciences, University of Naples Federico II, Naples, Italy.
Nutr Metab Cardiovasc Dis. 2010 Nov;20(9):656-61. doi: 10.1016/j.numecd.2009.05.017. Epub 2009 Aug 20.
Some nutraceuticals are prescribed as lipid-lowering substances. However, doubts remain about their efficacy. We evaluated the effects of a nutraceutical combination (NC), consisting of 500 mg berberine, 200mg red yeast rice and 10mg policosanols, on cholesterol levels and endothelial function in patients with hypercholesterolemia.
In this single centre, randomized, double-blind, placebo-controlled study, 50 hypercholesterolemic patients (26 males and 24 females, mean age 55±7 years, total cholesterol 6.55±0.75 mmol/l, BMI 28±3.5) were randomized to 6 weeks of treatment with a daily oral dose of NC (25 patients) or placebo (25 patients). In a subsequent open-label extension of 4 weeks, the whole sample received NC. The main outcome measure was decrease total cholesterol (C) levels in the NC arm. Secondary outcome measures were decreased low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, and improved endothelial-dependent flow-mediated dilation (FMD) and insulin sensitivity in relation to NC. Evaluation of absolute changes from baseline showed significant reductions in NC versus placebo for C and LDL-C (C: -1.14±0.88 and -0.03±0.78 mmol/l, p<0.001; LDL-C: -1.06±0.75 and -00.4±0.54 mmol/l, p<0.001), and a significant improvement of FMD (3±4% and 0±3% respectively, p<0.05). After the extension phase, triglyceride levels decreased significantly from 1.57±0.77 to 1.26±0.63 mmol/l, p<0.05 and insulin sensitivity improved in a patient subgroup with insulin resistance at baseline (HOMA: from 3.3±0.4 to 2.5±1.3, p<0.05). No adverse effect was reported.
This NC reduces cholesterol levels. The reduction is associated with improved endothelial function and insulin sensitivity.
一些营养保健品被开为降脂药物。然而,其疗效仍存在争议。我们评估了一种营养保健品组合(NC),由 500 毫克黄连素、200 毫克红曲米和 10 毫克角鲨烷组成,对高胆固醇血症患者的胆固醇水平和内皮功能的影响。
在这项单中心、随机、双盲、安慰剂对照研究中,50 名高胆固醇血症患者(26 名男性和 24 名女性,平均年龄 55±7 岁,总胆固醇 6.55±0.75mmol/L,BMI 28±3.5)被随机分为 6 周的每日口服剂量 NC(25 名患者)或安慰剂(25 名患者)治疗。在随后的 4 周开放标签扩展期,所有患者均接受 NC 治疗。主要观察指标是 NC 组总胆固醇(C)水平的降低。次要观察指标为低密度脂蛋白胆固醇(LDL-C)和甘油三酯水平的降低,以及与 NC 相关的内皮依赖性血流介导的扩张(FMD)和胰岛素敏感性的改善。从基线的绝对变化评估显示,NC 与安慰剂相比,C 和 LDL-C 显著降低(C:-1.14±0.88 和-0.03±0.78mmol/L,p<0.001;LDL-C:-1.06±0.75 和-00.4±0.54mmol/L,p<0.001),FMD 显著改善(3±4%和 0±3%,分别为 p<0.05)。在扩展阶段后,甘油三酯水平从 1.57±0.77 降至 1.26±0.63mmol/L,p<0.05,并且基线胰岛素抵抗患者亚组的胰岛素敏感性改善(HOMA:从 3.3±0.4 降至 2.5±1.3,p<0.05)。没有报告不良反应。
NC 降低胆固醇水平。这种降低与内皮功能和胰岛素敏感性的改善有关。